202412142037

Status:

Tags: Haematology, pharmacology

DDAVP

1-deamino-8-D-arginin-vasopressin (DDAVP) is a synthetic analog of the antidiuretic hormone vasopressin

V2 specificity

well tolerated, safe & cheap

route of admin (for haemostasis / vWD)

• IV
  • 0.3 µg/kg diluted in 50-100 mL saline
  • infused over 30 minutes
  • (??capped doses of 15-20µg suggested to have similar effects)
• SC
  • 0.3 µg/kg
• IN
  • fixed doses of 300 µg in subjects of ≥50 kg BW
  • 150 µg in those <50 kg
    This treatment ↑ circulating FVIII/VWF 3-5x above basal levels within 30-60 min; high plasma FVIII and VWF concentrations last for 6-8 hours

Side effects, attributable to the vasomotor effect of the molecule, may include mild tachycardia, flushing and headache.
hypoNa, especially in children below the age of 2 (& during pregnancy?), may occur due to the antidiuretic properties of DDAVP, as well as volume overload; both are preventable by limiting fluid intake for 24 hours after the administration of DDAVP

generally C/I in individuals with cardiovascular disease (eg, coronary heart disease, cerebrovascular disease, and peripheral vascular disease) and/or ↑ risk of thrombosis

References